BILL ANALYSIS                                                                                                                                                                                                    



                                                                  AB 163
                                                                  Page  1

          Date of Hearing:   May 6, 2009

                        ASSEMBLY COMMITTEE ON APPROPRIATIONS
                                Kevin De Leon, Chair

                   AB 163 (Emmerson) - As Amended:  April 13, 2009 

          Policy Committee:                              HealthVote:17-0

          Urgency:     No                   State Mandated Local Program:  
          Yes    Reimbursable:              No

           SUMMARY  

          This bill requires health plans and health insurers to provide  
          coverage for amino acid-based elemental formulas (AAEF) for the  
          diagnosis and treatment of eosinophilic disorders (ED). 

           FISCAL EFFECT  

          1)According to the California Health Benefits Review Program  
            (CHBRP), annual costs of $478,000 (60% GF) to CalPERS to  
            comply with the requirements of this bill.  The GF portion of  
            these expenditures account for state-related health benefits  
            and not the costs of coverage associated with local  
            jurisdictions that contract with CalPERS as a benefits  
            administrator. The annual costs of treating AAEF is  
            approximately $13,900 per person when paid out-of-pocket by  
            families.  

          2)                           Additional costs of $7 million in  
            premiums paid in the private health insurance market  
            associated with individual and group coverage. Most of this  
            increase is offset by reduced out-of-pocket costs paid by  
            families for AAEF prior to the mandate.  


           COMMENTS  

           1)Rationale  .  This bill is sponsored by the American Partnership  
            for Eosinophilic Disorders. This bill requires health plans  
            and health insurers to provide coverage for formulas  
            prescribed by a physician and deemed medically necessary,  
            regardless of the delivery method for rare, serious  
            conditions. AAEF are nutritional formulas designed for  








                                                                  AB 163
                                                                  Page  2

            individuals who have an immune response to allergens found in  
            whole foods or formulas composed of whole proteins, fats,  
            and/or carbohydrates. 

          Health coverage often pays for the costs of elemental formulas  
            when administered by a gastric feeding tube, or G-tube, but  
            not when consumed orally, which costs considerably less. This  
            bill provides coverage regardless of mode of delivery.  Under  
            current law, 99% of insurance policies provide coverage AAEF  
            delivered through a feeding tube, while only 35% of insurance  
            policies cover for AAEF administered orally. As a result of  
            this bill, an estimated 600 people needing coverage statewide  
            will gain coverage for AAEF. 
           
           2)Background  . ED occurs when eosinophils, a type of white blood  
            cell, is found in above-normal amounts in the body including  
            in the esophagus, stomach, and small and large intestines.  
            Producing too many eosinophils can cause chronic inflammation,  
            resulting in tissue damage.  Common symptoms include  
            difficulty swallowing, nausea and vomiting, failure to thrive,  
            malnutrition, abdominal or chest pain, and difficulty  
            sleeping. ED is a rare condition impacting 8,500 Californians.

           3)Industry Cost Concerns  . Opponents of this bill indicate  
            legislatively mandated health benefits increase costs and  
            limit insurer, employer, and individual choices with respect  
            to a variety of health benefits. Opponents indicate health  
            mandates can hinder compliance with evidence-based medical  
            standards that reflect new medical technology or other  
            advances in knowledge.  When considered together, mandates may  
            also hinder the ability of insurers and employers to offer a  
            wide range of affordable products to consumers with a variety  
            of health care needs.  
           
          4)Related Legislation  . There are more than two dozen current law  
            health mandates, established over the last two decades, to  
            provide coverage for specified services such as cancer  
            screenings and treatment. There are another handful of  
            mandates to offer coverage for a number of other health  
            services. 

          AB 2174 (Laird) in 2008 was similar to this bill and was held on  
            the Suspense File of the Senate Appropriations Committee. 

          AB 30 (Evans) in 2008 required specified health plans and  








                                                                  AB 163
                                                                  Page  3

            insurers to provide coverage of testing for, and treatment of,  
            inborn errors of metabolism (IEM). AB 30 was vetoed due to  
            cost concerns of health mandates. 
           
          5)Other Health Mandates in the Current Session  . 

             a)   There are nine health mandates under legislative  
               consideration this year, including AB 163. Other proposed  
               health mandates include: 

               i)   AB 56 (Portantino): mammography notification
               ii)  AB 98 (De La Torre): maternity coverage
               iii) AB 214 (Chesbro): durable medical equipment coverage 
               iv) AB 244 (Beall): mental health parity 
               v) AB 259 (Skinner): access to nurse midwives 
               vi) AB 513 (De Leon): lactation consultant coverage 
               vii) SB 158 (Wiggins): HPV vaccine coverage 
               viii) SB 161 (Wright): chemotherapy treatment 

             b)   Two other bills address specification of current law  
               mandates with respect to minimum coverage or loosening of  
               current law mandates. These two bills are: 

               i) AB 786 (Jones): standardization of individual market  
               products 
               ii) SB 92 (Aanestad): out-of-state carrier coverage 

           

           Analysis Prepared by  :    Mary Ader / APPR. / (916) 319-2081